Immune cytopenias as a continuum in inborn errors of immunity: An in-depth clinical and immunological exploration.
DiGeorge syndrome
autoimmune hemolytic anemia
autoimmune lymphoproliferative syndrome
autoimmune neutropenia
common variable immune deficiency
immune cytopenias
immune thrombocytopenia
inborn errors of immunity
Journal
Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
01
02
2021
received:
11
11
2020
accepted:
17
02
2021
pubmed:
11
4
2021
medline:
16
10
2021
entrez:
10
4
2021
Statut:
ppublish
Résumé
Immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and autoimmune neutropenia (AIN) are disorders characterized by immune-mediated destruction of hematopoietic cell lineages. A link between pediatric immune cytopenias and inborn errors of immunity (IEI) was established in particular in the combined and chronic forms. Aim of this study is to provide clinical-immunological parameters to hematologists useful for a prompt identification of children with immune cytopenias deserving a deeper immunological and genetic evaluation. We retrospectively collected 47 pediatric patients with at least one hematological disorder among which persistent/chronic ITP, AIHA, and AIN, aged 0-18 years at onset of immune cytopenias and/or immune-dysregulation. The cohort was divided into two groups (IEI+ and IEI-), based on the presence/absence of underlying IEI diagnosis. IEI+ group, formed by 19/47 individuals, included: common variable immune deficiency (CVID; 9/19), autoimmune lymphoproliferative syndrome (ALPS; 4/19), DiGeorge syndrome (1/19), and unclassified IEI (5/19). IEI prevalence among patients with ITP, AIHA, AIN, and Evans Syndrome was respectively of 42%, 64%, 36%, and 62%. In IEI+ group the extended immunophenotyping identified the presence of statistically significant (p < .05) specific characteristics, namely T/B lymphopenia, decrease in naїve T-cells%, switched memory B-cells%, plasmablasts%, and/or immunoglobulins, increase in effector/central memory T-cells% and CD21low B-cells%. Except for DiGeorge and three ALPS patients, only 2/9 CVID patients had a molecular diagnosis for IEI: one carrying the pathogenic variant CR2:c.826delT, the likely pathogenic variant PRF1:c.272C> and the compound heterozygous TNFRSF13B variants p.Ser144Ter (pathogenic) and p.Cys193Arg (variant of uncertain significance), the other one carrying the likely pathogenic monoallelic variant TNFRSF13B:p.Ile87Asn. The synergy between hematologists and immunologists can improve and fasten diagnosis and management of patients with immune cytopenias through a wide focused clinical/immunophenotypical characterization, which identifies children worthy of IEI-related molecular analysis, favouring a genetic IEI diagnosis and potentially unveiling new targeted-gene variants responsible for IEI phenotype.
Sections du résumé
BACKGROUND
Immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and autoimmune neutropenia (AIN) are disorders characterized by immune-mediated destruction of hematopoietic cell lineages. A link between pediatric immune cytopenias and inborn errors of immunity (IEI) was established in particular in the combined and chronic forms.
OBJECTIVE
Aim of this study is to provide clinical-immunological parameters to hematologists useful for a prompt identification of children with immune cytopenias deserving a deeper immunological and genetic evaluation.
METHODS
We retrospectively collected 47 pediatric patients with at least one hematological disorder among which persistent/chronic ITP, AIHA, and AIN, aged 0-18 years at onset of immune cytopenias and/or immune-dysregulation. The cohort was divided into two groups (IEI+ and IEI-), based on the presence/absence of underlying IEI diagnosis. IEI+ group, formed by 19/47 individuals, included: common variable immune deficiency (CVID; 9/19), autoimmune lymphoproliferative syndrome (ALPS; 4/19), DiGeorge syndrome (1/19), and unclassified IEI (5/19).
RESULTS
IEI prevalence among patients with ITP, AIHA, AIN, and Evans Syndrome was respectively of 42%, 64%, 36%, and 62%. In IEI+ group the extended immunophenotyping identified the presence of statistically significant (p < .05) specific characteristics, namely T/B lymphopenia, decrease in naїve T-cells%, switched memory B-cells%, plasmablasts%, and/or immunoglobulins, increase in effector/central memory T-cells% and CD21low B-cells%. Except for DiGeorge and three ALPS patients, only 2/9 CVID patients had a molecular diagnosis for IEI: one carrying the pathogenic variant CR2:c.826delT, the likely pathogenic variant PRF1:c.272C> and the compound heterozygous TNFRSF13B variants p.Ser144Ter (pathogenic) and p.Cys193Arg (variant of uncertain significance), the other one carrying the likely pathogenic monoallelic variant TNFRSF13B:p.Ile87Asn.
CONCLUSION
The synergy between hematologists and immunologists can improve and fasten diagnosis and management of patients with immune cytopenias through a wide focused clinical/immunophenotypical characterization, which identifies children worthy of IEI-related molecular analysis, favouring a genetic IEI diagnosis and potentially unveiling new targeted-gene variants responsible for IEI phenotype.
Identifiants
pubmed: 33838017
doi: 10.1002/iid3.420
pmc: PMC8127541
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
583-594Informations de copyright
© 2021 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Références
Front Pediatr. 2019 Jul 23;7:304
pubmed: 31396497
Clin Vaccine Immunol. 2006 Mar;13(3):329-32
pubmed: 16522773
Scand J Immunol. 2019 Nov;90(5):e12809
pubmed: 31322747
Front Pediatr. 2015 Sep 29;3:79
pubmed: 26484337
Pediatr Blood Cancer. 2018 Oct;65(10):e27260
pubmed: 29856527
Cytometry B Clin Cytom. 2008 Sep;74(5):261-71
pubmed: 18561200
J Allergy Clin Immunol. 2017 Nov;140(5):1388-1393.e8
pubmed: 28192146
Immunol Res. 2014 Oct;60(1):132-44
pubmed: 24668296
Blood. 2012 Oct 18;120(16):3318-25
pubmed: 22859611
Nat Immunol. 2011 Jun;12(6):467-71
pubmed: 21739668
Curr Opin Pediatr. 2019 Dec;31(6):851-862
pubmed: 31693597
J Allergy Clin Immunol. 2016 Jan;137(1):3-17
pubmed: 26768758
Front Immunol. 2018 Aug 02;9:1758
pubmed: 30116245
Blood. 2014 Oct 9;124(15):2337-44
pubmed: 25163701
J Clin Pathol. 2016 Aug;69(8):672-6
pubmed: 27153873
Cent Eur J Immunol. 2017;42(3):244-251
pubmed: 29204088
J Hematol. 2017 Oct;6(4):81-86
pubmed: 32300398
Blood. 2019 Jul 4;134(1):9-21
pubmed: 30940614
Immun Inflamm Dis. 2021 Jun;9(2):583-594
pubmed: 33838017
J Allergy Clin Immunol Pract. 2019 Sep - Oct;7(7):2369-2376
pubmed: 30922987
J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1763-1770
pubmed: 30776527
J Allergy Clin Immunol Pract. 2019 Sep - Oct;7(7):2377-2378
pubmed: 31495434
Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13451-6
pubmed: 19666505
Sci Rep. 2017 Jan 05;7:39710
pubmed: 28054583
Blood. 2017 Apr 20;129(16):2266-2279
pubmed: 28202457
Pediatr Blood Cancer. 2016 Feb;63(2):292-8
pubmed: 26397379
J Immunol Res. 2016;2016:8390356
pubmed: 27123465
Front Immunol. 2019 Mar 15;10:447
pubmed: 30949166
Nat Immunol. 2014 Jan;15(1):88-97
pubmed: 24165795
Haematologica. 2011 May;96(5):655-63
pubmed: 21228033